investigational new drug (IND)

Applications and Submissions

Investigational new drug banner Investigational new drug banner

Obtaining Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) is a critical step towards beginning your clinical trials in the United States. Getting here required hard work and a great Pre-IND Meeting strategy (which we can help manage), and you still need FDA approval on your IND application before you can ship your drug across state lines and begin clinical trials.

The sooner you can begin your clinical trials, the sooner your product will be on the market. To prevent any hiccups in this process, your final IND submission must be error-free and contain all required information including animal pharmacology and toxicology studies, manufacturer and investigator information, along with detailed protocols for your upcoming clinical trials.

No matter where you are in the IND application or submission process, our IND consultants can provide guidance to assist with the remaining steps.

Fill out the form on the right to contact our IND consultants to learn more and get started today!

What is an IND?

An Investigational New Drug Application (IND) is a request for authorization submitted by a Sponsor to the FDA so the Sponsor can conduct clinical trials for unapproved drugs. The purpose of an IND application is to allow Sponsors to start conducting clinical trials on humans, and approval to ship the drugs across state lines to conduct these trials.

Types of INDs

INDs fall into two categories:

Commercial IND: Commercial INDs are used when the Sponsor intends to bring the drug to the open market. This means commercial INDs can apply to drugs created by non-profit groups who intend to eventually put the drug on the open market. The application process and timeline for a Commercial IND is much longer and more complex than for a Research IND.

Research IND: Research INDs are used when the intention is to prove efficacy for a new indication of an already approved drug. Research IND applications are submitted by physicians, and with a process that is less complex than Commercial INDs. For example, Research INDs typically involve fewer investigators and are often done at a single testing site.

How to Submit an IND Application

Your IND application will request authorization from the FDA to administer an investigational drug/biological product to humans and must be approved before you transport your product across state lines to clinical sites. The requirements for an IND submission are complicated and can be hard to understand. For example, Commercial IND applications must be submitted through the FDA’s Electronic Submissions Gateway, while Research IND applications can be submitted in paper-form to the relevant address. This is just one example of the complexities within the IND application and submission process.

As such, working with an experienced FDA consultant will help assure you’re equipped and on track. ProPharma will work with you to make sure your IND application meets the FDA’s stringent IND filing requirements and contains all of the necessary components.

Partner with us!

IND Filing Requirements

Each IND application should include the following:

  • Form FDA 1571 (IND application cover letter)
  • Form FDA 1572 (Investigator's statement)
  • Form FDA 3674 (Certification requirement & mandatory registration and reporting of results for applicable clinical trials through ClinicalTrials.gov.)
  • Table of contents
  • Introductory statement
  • General investigational plan
  • Investigator's brochure
  • Protocol(s): study protocol(s), investigator data, facilities data, Institutional Review Board (IRB)
  • Chemistry, manufacturing, and control (CMC) data, including environmental assessment or claim for the exclusion (assuming the draft of CMC information exists)
  • Nonclinical: pharmacology and toxicology data
  • Clinical: previous human experience
  • Additional information to support the IND filing

Together, we will carefully review the IND application, and our staff will provide you with a final copy that is FDA ready. The IND application will go into effect 30 days after the FDA receives the application (unless subject to a clinical hold), or earlier if the agency notifies the Sponsor that clinical trials can begin.

Get Expert Guidance From an IND Consultant for Your Upcoming Submission

ProPharma will guide you through every step of the IND submission process and ensure your application is error-free to meet filing requirements and ensure a successful interaction with the FDA. To learn more about how ProPharma can help you develop a successful IND application for submission to the FDA, contact us today.

News & Insights

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

Efficiency and Compliance: Mastering Legal Case Processing in Pharmacovigilance

August 3, 2026

Efficiency and Compliance: Mastering Legal Case Processing in Pharmacovigilance

Explore strategies for efficient legal case processing in pharmacovigilance, ensuring compliance and enhancing patient safety amidst rising litigation challenges.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

News & Insights

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

Efficiency and Compliance: Mastering Legal Case Processing in Pharmacovigilance

August 3, 2026

Efficiency and Compliance: Mastering Legal Case Processing in Pharmacovigilance

Explore strategies for efficient legal case processing in pharmacovigilance, ensuring compliance and enhancing patient safety amidst rising litigation challenges.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Previous Resource Arrow Next Resource Arrow
From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Previous Webinar Arrow Next Webinar Arrow